Search

The article discusses the impact of cholesterol-mediated lysosomal dysfunction in APOE4 astrocytes on a-synuclein pathology in human brain tissue. Researchers developed an iPSC-based 3D model called miBrain to study protein inclusions in the human brain, finding increased pathogenic phosphorylation and aggregation of a-synuclein in APOE4 miBrain. The study highlights the role of astrocytes and cholesterol in APOE4-mediated pathologies, offering potential therapeutic opportunities. This preprint has not yet undergone peer review. [Extracted from the article]

The article from Drug Week discusses a study conducted by the Chinese Academy of Sciences on the effects of aspirin on protein degradation and clearance of a-synuclein aggregates. The research found that aspirin impairs proteasome activity, leading to inhibition of proteasomal degradation, while promoting K63-linked ubiquitination. This mechanism was shown to reduce a-synuclein in cells, neurons, and Parkinson's disease model mice, indicating potential therapeutic implications. The study provides insights into aspirin's diverse pharmacological effects and its potential for future drug development efforts. [Extracted from the article]

The article discusses a newly launched clinical trial, NCT06812702, focusing on identifying and tracking motor symptoms in prodromal and clinical Parkinson's Disease (PD) using remote monitoring. The study involves a one-year longitudinal biomarker study recruiting idiopathic RBD patients, PD patients, and healthy controls, who will receive a smartphone with the Roche PD Mobile Application for monitoring. The trial aims to validate an immunohistochemistry skin biopsy assay for detecting pathological alpha-synuclein in the peripheral nerves of the skin, with a primary completion date of December 31, 2025. [Extracted from the article]

Researchers from Zhengzhou University in Henan, China, have proposed a hypothesis involving deep cervical lymphovenous bypass surgery as a potential treatment for Parkinson's disease. The procedure aims to improve the brain's lymphatic system function by creating a pathway for drainage, potentially reducing the accumulation of alpha-synuclein in the brain. If validated, this hypothesis could offer a new approach to treating Parkinson's disease and other neurodegenerative disorders. The research has been peer-reviewed and provides insights into addressing the increasing global public health concern of Parkinson's disease. [Extracted from the article]

A recent study conducted by the National Center for Nanoscience and Technology of China has developed a nanoparticle-based wireless deep brain stimulation system to treat Parkinson's disease. The system targets dopamine neurons in the substantia nigra, eliminating alpha-synuclein aggregates and restoring degenerated dopamine neurons. This innovative approach shows promise in reversing the effects of Parkinson's disease by utilizing nanotechnology and photothermal wireless deep brain stimulation. [Extracted from the article]

The article discusses the impact of the p.A53T mutation on astrocytes derived from induced pluripotent stem cells of Parkinson's disease patients. It highlights the role of astrocytes in contributing to neurodegeneration in Parkinson's disease by affecting protein quality control mechanisms. The study suggests that astrocytes may play a critical role in the pathology of Parkinson's disease, emphasizing the need for further research in this area. [Extracted from the article]

A preprint abstract discusses the discovery of a novel long non-coding RNA (lncRNA) called FAM151B-DT, which is reduced in various neurodegenerative diseases. Silencing FAM151B-DT enhances tau aggregation and blocks autophagy, leading to the accumulation of tau and ?-synuclein. Increasing FAM151B-DT expression promotes autophagic flux, reduces phospho-tau and ?-synuclein, and reduces tau aggregation, suggesting it as a potential molecular target for neurodegenerative diseases. The research has not yet been peer-reviewed. [Extracted from the article]

A recent preprint abstract discussed the relationship between Alzheimer's Disease (AD) and Parkinson's Disease, specifically focusing on the role of alpha-Synuclein (-Syn) co-pathology in driving tau accumulation in the brain. The study found that brains with both AD and -Syn co-pathology expressed higher levels of tau, suggesting a link between the two diseases in driving dementia-related pathology. This research sheds light on a previously unknown connection between AD and Parkinson's Disease, highlighting the importance of understanding the molecular basis for cognitive decline in these conditions. [Extracted from the article]

Researchers from a Federal University in Brazil conducted a study on the effects of a hydroalcoholic extract of Eugenia uniflora on depressive-like behavior in female rats exposed to MPTP, a model for Parkinson's disease. The study found that the extract reversed depressive-like behavior and modulated apoptotic pathways and a-synuclein levels in the hippocampus, suggesting potential neuroprotective effects. The research was supported by various funding sources and was published in the journal Brain Sciences. For more information, readers can access the full article for free online. [Extracted from the article]

A recent study from the University of California San Diego (UCSD) explores the use of antisense oligonucleotide-based technology to target a-synuclein in Dementia with Lewy bodies (DLB) disease. The research suggests that systemically-delivered ApoB11:ASO a-syn could be a safe and effective disease-modifying treatment for DLB and potentially other synucleinopathies. This study highlights the potential of this approach in reducing a-syn aggregates in the brain and improving neuronal survival, motor performance, and cognition in DLB mice. [Extracted from the article]

A study published in Pain & Central Nervous System Week discusses the detection of alpha-synuclein seeding activity in tear fluid as a potential non-invasive biomarker for Parkinson's disease diagnosis. The study utilized the alpha-synuclein seeding amplification assay to detect misfolded alpha-synuclein aggregation in tear fluid samples from Parkinson's disease patients. Results showed that over 55% of Parkinson's disease patients tested positive for alpha-synuclein seeding activity, highlighting the potential of tear fluid as a novel medium for early diagnosis and disease progression monitoring. The study also compared results from tear fluid and cerebrospinal fluid samples, showing consistent seeding activity across both biofluids. [Extracted from the article]

Researchers from Fujita Health University in Japan have published a study on Parkinson's disease, focusing on the disruption of brain energy homeostasis in the condition. The study highlights how deficits in ATP production can lead to a-synuclein accumulation, impaired autophagy, and neurodegeneration, impacting both motor and non-motor symptoms. The researchers propose an 'ATP Supply-Demand Mismatch Model' to explain the pathogenesis of Parkinson's disease. For more information, the study can be found in Frontiers in Molecular Neuroscience. [Extracted from the article]

Researchers at the University of Michigan Medical School have conducted a study on the interaction of tissue plasminogen activator (tPA) with NMDAR1 in neurodegeneration. The research focused on tPA's role in the substantia nigra and its impact on Parkinson's disease pathology. Findings suggest that tPA deficiency can protect dopaminergic neurons from degeneration and reduce neuroinflammation. The study also highlights a potential therapeutic intervention targeting the tPA-NMDAR1 interaction for Parkinson's disease. [Extracted from the article]

The article discusses the role of calcineurin in regulating GAP-43, which is crucial for neurite and synapse formation and protection against a-synuclein-induced degeneration. The study highlights how FK506, an FDA-approved compound that inhibits calcineurin activity, can offer neuroprotection against a-synuclein pathology in a rat model. The findings suggest that the phosphorylation of GAP-43, regulated by calcineurin, plays a critical role in promoting neurite branching and synapse formation, providing insights into potential mechanisms for neuroprotection in neurons under proteotoxic stress. [Extracted from the article]

Researchers from Case Western Reserve University School of Medicine have focused on nerve tissue proteins, specifically alpha-synuclein and inflammaging. The study explores the potential link between alpha-synuclein, aging, and Parkinson's disease, suggesting that chronic inflammation associated with aging may worsen PD symptoms. The research highlights the role of alpha-synuclein in the immune system and its contribution to inflammaging, providing valuable insights into neurodegenerative pathologies. [Extracted from the article]

The article explores the impact of lysine acetylation on alpha-synuclein, a protein associated with neurodegenerative diseases like Parkinson's and Multiple System Atrophy. Researchers used non-canonical amino acid mutagenesis to investigate disease-relevant acetylation sites on alpha-synuclein, finding that acetylation at lysine 12, 43, and 80 had significant effects on protein behavior. The study suggests that acetylation at lysine 80 could potentially inhibit protein aggregation without negative effects on healthy cells, offering insights into potential therapeutic strategies. The research is available as a preprint and has not yet undergone peer review. [Extracted from the article]

Researchers from Mashhad University of Medical Sciences conducted a study on the effects of trans-sodium crocetinate (TSC) on Parkinson-like symptoms induced by Bisphenol A (BPA) in rats. The study found that TSC reduced oxidative stress, decreased alpha-synuclein expression, and improved motor function in the rats. The researchers concluded that TSC shows promise as a potential treatment for Parkinson's disease. [Extracted from the article]

A recent study conducted by Baylor University College of Medicine focused on nerve tissue proteins and their role in Parkinson's disease. The research involved creating mice with a specific mutation in the alpha-Synuclein gene, which led to early symptoms such as olfactory deficits and gastrointestinal dysfunction before motor abnormalities appeared. This study sheds light on the progression of Parkinson's disease and may aid in developing future therapies. The research was supported by various organizations and has been peer-reviewed, providing valuable insights into the pathogenesis of PD. [Extracted from the article]

A patent application by inventors from the Icahn School of Medicine at Mount Sinai proposes a method to decrease degeneration of retinal ganglion cells (RGCs) to address visual impairment and blindness caused by various conditions like glaucoma. The method involves administering a composition to increase the activity of calcium-calmodulin dependent kinase (CaMK) or cyclic-AMP response element-binding protein (CREB) in the subject, potentially preventing RGC loss and vision impairment. The patent application aims to develop effective neuroprotective approaches for preserving RGCs and their function, particularly in high-risk individuals and patients with conditions like glaucoma, diabetic retinopathy, retinal ischemia, and optic nerve injury. [Extracted from the article]

A recent study from Ulm University Medical Center explores the relationship between a-synuclein fibrils and HIV-1 infection in human T cells, macrophages, and microglia. The research suggests that these fibrils, associated with neurological diseases, enhance viral entry and replication in the central nervous system. The findings indicate a potential detrimental interplay between HIV-1 and brain amyloids, which may contribute to the development of neurodegenerative diseases. For more information, the full article is available in Nature Communications. [Extracted from the article]

A patent application titled "Fecal Transplants For Reversing Motor And Gut Symptoms In Neurodevelopmental Disorders" explores the potential benefits of administering fecal microbiota from healthy, younger subjects to individuals with neurodegenerative disorders like Parkinson's disease. The application suggests that this treatment method may improve gastrointestinal functions and relieve motor deficit symptoms in affected individuals. The research aims to address the impact of gut microbiota on brain health and complex behaviors, highlighting the potential of younger microbiomes to benefit aging brains. [Extracted from the article]

The article discusses a study on transgenic A53T mice with astrocytic alpha-synuclein aggregates in dopamine and striatal regions, shedding light on the role of astrocytes in Parkinson's disease. The research suggests that astrocytes play a crucial role in clearing alpha-synuclein and supporting the substantia nigra pars compacta, potentially impacting the progression of the disease. The findings highlight the importance of understanding the early involvement of astrocytes in Parkinson's disease for a biological definition of the condition. [Extracted from the article]

Researchers at Universidad Mayor in Temuco, Chile, have made significant progress in advancing the diagnosis of Parkinson's disease through the detection of alpha-synuclein aggregates in minimally invasive samples. This protein plays a crucial role in the pathophysiology of Parkinson's and can differentiate it from other neurodegenerative disorders with similar symptoms. The seed amplification assay (SAA) has shown promise in detecting alpha-synuclein aggregates in peripheral samples like skin, olfactory mucosa, saliva, and blood, but the lack of standardized protocols hinders its clinical application. Standardizing protocols is crucial for improving assay reliability and accurately identifying patients for emerging therapies. [Extracted from the article]

A recent study conducted at Capital Medical University explored the role of microglia in Parkinson's disease, specifically focusing on their contribution to neurodegeneration. By depleting microglia in a mouse model of Parkinson's disease triggered by a-synuclein overexpression, researchers observed reduced neurodegeneration and remodeling of the extracellular matrix. The findings suggest that microglia may have adverse effects during neurodegeneration and that their depletion could aid in recovery following neuronal insult. For more information, the full article can be accessed for free at the npj Parkinson's Disease website. [Extracted from the article]

A study conducted by Louisiana State University explores the potential regulation of the immune modulator Tetraspanin Cd81 by the protein alpha-synuclein in melanoma. The research suggests that high levels of alpha-synuclein and CD81 in melanoma cells and immune cells may drive invasion, migration, and create an immunosuppressive microenvironment, contributing to aggressive melanomas. This peer-reviewed study sheds light on the relationship between these proteins and their impact on melanoma progression and immune response. [Extracted from the article]

A recent study conducted at the University of California San Diego (UCSD) explored the downregulation of a-synuclein in a mouse model of Alzheimer's Disease (AD). The research focused on the therapeutic effects of downregulating a-syn in AD mice, leading to reduced amyloid beta plaques burden, rescued neuronal loss, and improved spatial memory function. The findings suggest that knocking down a-syn could be a promising future therapeutic strategy in AD, highlighting potential pathways for a-syn-mediated vulnerability. The study was published in Alzheimer's & Dementia and can be accessed for free online. [Extracted from the article]

Researchers from Ludwig-Maximilians-University in Munich, Germany, conducted a study comparing the diagnostic efficacy of 123Iodo-metaiodobenzylguanidine SPECT/CT in patients with arrhythmogenic right ventricular dysplasia (ARVC) and a-synucleinopathies. The study found that patients with a-synucleinopathies showed significantly lower cardiac innervation compared to ARVC patients in both semi-quantitative and quantitative examinations. The research suggests that quantitative examination offers an advantage in distinguishing between these two diseases, and disease-specific ranges should be used for accurate diagnosis. For more information, refer to the article "Diagnostic Efficacy of 123Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and a-Synucleinopathies" published in Diagnostics. [Extracted from the article]

The article discusses a study on Parkinson's disease conducted by the National Neuroscience Institute of Singapore. The research focuses on the abnormal aggregation of misfolded a-synuclein protein in the brain, which is a central pathological event in Parkinson's disease. The study highlights the potential of a blood-based a-Syn seeding amplification assay for enhancing Parkinson's disease diagnosis, progression monitoring, prognosis prediction, and anti-PD therapy. The research provides valuable insights into the disease and its potential diagnostic and therapeutic implications. [Extracted from the article]

A recent study conducted at the University of California San Diego (UCSD) explored the relationship between subjective cognitive decline (SCD) in older adults and the presence of amyloid and a-synuclein pathologies. The study found that participants with both amyloid and a-synuclein pathologies exhibited the greatest SCD, as reported by both participants and study partners. These findings suggest the importance of considering co-pathologies in understanding the etiologies of SCD in older adults without dementia. The research was published in Innovation in Aging and can be accessed for further information. [Extracted from the article]

A recent study conducted by the Russian Academy of Sciences explored the potential link between assisted reproductive technologies (ARTs) and Parkinson's Disease (PD) in offspring. The research focused on motor dysfunction, neuronal density, and alpha-synuclein accumulation in the substantia nigra of mice born via ART compared to natural mating. The findings suggest a possible association between modern ARTs and an increased predisposition to neurodegenerative processes, including PD symptoms in offspring. [Extracted from the article]

A study conducted at Shandong University in the People's Republic of China focused on the role of Otud5 in protecting dopaminergic neurons by promoting the degradation of alpha-synuclein in Parkinson's Disease. The research highlighted the importance of E3 ligases in regulating the degradation of alpha-synuclein, a key pathogenic factor in Parkinson's Disease. The findings suggest a novel mechanism for regulating alpha-synuclein degradation and offer a potential therapeutic strategy to alleviate dopaminergic neurodegeneration. [Extracted from the article]

The article discusses new research on nerve tissue proteins conducted at the Weldon School of Biomedical Engineering. The study focuses on the seeding of Lewy pathology in specific brain regions, leading to distinct cellular and dendritic vulnerabilities in the cortex. The findings suggest a link between Layer-5 dendritic vulnerabilities and translaminar beta event dysfunction, which could help differentiate similar synucleinopathies. For more information, readers can access the full article in Nature Communications. [Extracted from the article]

A recent study conducted at Martin-Luther-University in Saale, Germany, explored the prognostic role of beta-synuclein, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in predicting functional outcomes after acute ischemic stroke (AIS). The research involved measuring serum concentrations of these biomarkers in 213 patients with moderate-to-severe AIS, revealing associations with clinical characteristics, mortality, and functional outcomes. The study suggests that serum beta-synuclein levels may serve as a valuable indicator of synaptic damage/dysfunction and could aid in predicting clinical outcomes in AIS patients. [Extracted from the article]

A recent study from the University of Auckland delves into the differences in a-synuclein proteoforms between multiple system atrophy (MSA) and Parkinson's disease (PD). By utilizing a multiplex immunohistochemical approach, researchers found that MSA exhibits more diverse aggregate morphologies compared to PD, with distinct glial-specific changes between the two diseases. The study highlights the importance of detecting a-Syn, particularly the N-terminus, to accurately diagnose and differentiate between a-synucleinopathies, paving the way for improved diagnostic methods for neurodegenerative diseases. [Extracted from the article]

The article discusses the relationship between pathological a-synuclein, tau, and granulovacuolar degeneration in neurodegenerative conditions such as Lewy body dementia and Alzheimer's disease. A mouse model of limbic-predominant a-synucleinopathy was used to study this relationship, revealing that a-synuclein pathology can independently elicit granulovacuolar degeneration. The findings suggest a parallel mechanism of cellular dysfunction between tau and GVBs, highlighting the broader relevance of this process to neurodegeneration. The study emphasizes the importance of understanding the pathobiology of Lewy body dementia. [Extracted from the article]

Research from the Van Andel Institute explores the impact of chronic urinary tract infections (UTIs) on the brain in a humanized -synuclein mouse model, shedding light on potential connections to neurodegenerative diseases like multiple system atrophy (MSA) and Parkinson's disease. The study reveals that recurrent UTIs can lead to persistent microglial changes in various brain regions, affecting behavior and neuroinflammation. Further investigation is needed to understand the role of UTIs in the progression of synucleinopathies and related neurological disorders. [Extracted from the article]

A patent has been issued for a nitrogen-containing saturated heterocyclyl derivative by Sumitomo Pharma Co. Ltd., aimed at treating neurodegenerative diseases like Parkinson's. The compound is designed to suppress or reduce the accumulation of abnormal protein aggregates in the brain, potentially offering therapeutic effects for various diseases. This patent represents a significant development in the pursuit of disease-modifying drugs for conditions like Parkinson's disease. [Extracted from the article]

University of Sydney researchers have conducted a study on neurodegeneration in Parkinson's disease, focusing on the role of astrocytes and toll-like receptor 2 (TLR2) activation. The research found that TLR2 activation impairs the autophagy lysosomal pathway, leading to a-synuclein pathology and degeneration of dopaminergic neurons. This study highlights the potential therapeutic target of TLR2 in Parkinson's disease and the importance of addressing astrocyte dysfunction in disease progression. [Extracted from the article]

Researchers at the Center for Neurodegenerative Diseases have provided new insights into Parkinson's Disease, focusing on the role of a-Synuclein (a-syn) in the disease. The study highlights how pathological a-syn accumulation in various cells contributes to neuroinflammation and neurodegeneration in Parkinson's Disease. The research suggests that targeting a-syn could be a potential therapeutic approach for the condition. [Extracted from the article]

Researchers from Central South University in China have developed a new immunofluorescence detection method for Parkinson's disease biomarkers using silver nanoparticles. The study focused on identifying a-synuclein, a key biomarker associated with Parkinson's disease, with high sensitivity and specificity. The method showed promising results in terms of detection limits, specificity, and potential clinical applications for diagnosing and monitoring Parkinson's disease. This research provides valuable insights into the development of innovative diagnostic tools for neurodegenerative conditions like Parkinson's disease. [Extracted from the article]

The article discusses the widespread distribution of α-synuclein oligomers in LRRK2-related Parkinson's Disease. It highlights the differences in pathological findings between typical Parkinson's Disease and LRRK2-PD, emphasizing the presence of SYN oligomers even in cases without Lewy-related pathology. The study suggests that targeting SYN oligomers may be a potential therapeutic strategy for LRRK2-PD, regardless of the presence of Lewy-related pathology. The findings indicate that SYN oligomers may accumulate in the brain without progressing to form Lewy-related pathology, particularly in cases with specific LRRK2 mutations. [Extracted from the article]

A study conducted by the National Institute of Neurological Disorders and Stroke in Bethesda, Maryland, focused on autonomic synucleinopathies, including Parkinson's disease and multiple system atrophy (MSA). The research found decreased urinary excretion rates of norepinephrine and dopamine in individuals with these conditions compared to controls. This suggests dysfunctions in the renal sympathetic noradrenergic system or the DOPA-dopamine autocrine-paracrine system. The study was peer-reviewed and provides valuable insights into the catecholaminergic abnormalities in autonomic synucleinopathies. [Extracted from the article]

A recent study from Case Western Reserve University School of Medicine explores the connection between mitochondrial dysfunction and alpha-synuclein aggregation in Parkinson's Disease (PD). The research identifies the loss of branched chain ketoacid dehydrogenase kinase (BCKDK) as a mitochondrial risk factor that exacerbates aSyn pathology by disrupting Complex I function. Findings suggest that restoring BCKDK expression could potentially mitigate mitochondrial impairment and neurodegeneration in PD. This study sheds light on potential therapeutic targets for addressing PD-related mitochondrial dysfunction and aSyn pathology. [Extracted from the article]

A recent report from Cornell University explores the impact of alpha-synuclein on mitochondrial quality control in Parkinson's disease. The research highlights the crucial role of maintaining healthy mitochondria for neuronal survival and the implications of impaired mitochondrial quality control in Parkinson's pathology. Understanding how alpha-synuclein influences mitochondrial maintenance may be key to uncovering Parkinson's disease mechanisms and potential therapeutic targets. For more information, readers can access the full article titled "Alpha-Synuclein Effects on Mitochondrial Quality Control in Parkinson's Disease" in Biomolecules. [Extracted from the article]

The article discusses a clinical trial, NCT06745011, focusing on detecting Parkinson's disease at an early stage when damage is limited to the peripheral nervous system. The trial aims to collect biological material to establish a biobank for prognostic biomarkers related to Parkinson's Disease and other neurodegenerative diseases. The study involves assessing REM sleep behavior disorder and related conditions over a five-year period, utilizing various diagnostic criteria and imaging methods. The trial is observational, enrolling 100 participants with idiopathic polyneuropathy and specific criteria, with a completion date set for May 1, 2031. [Extracted from the article]

The University of Hull conducted research on nerve tissue proteins, specifically a-synuclein, and its role in platelet function. The study found that a-synuclein deletion in mice led to impaired platelet aggregation, secretion, and adhesion, resulting in prolonged bleeding times. The research suggests that a-synuclein regulates platelet secretion by facilitating SNARE complex formation, which is essential for haemostasis. This study provides valuable insights into the mechanisms underlying platelet function and could have implications for conditions such as haemostasis, wound healing, inflammation, and atherosclerosis. [Extracted from the article]

A patent has been issued for alpha-synuclein single domain antibodies by New York University, aiming to address deficiencies in current approaches to targeting protein aggregates associated with neurodegenerative diseases like Alzheimer's and Parkinson's. The patent describes antibodies with specific amino acid sequences that can inhibit, treat, and diagnose a-synucleinopathies in subjects. This innovation could potentially lead to the development of new therapies and diagnostic tools for diseases characterized by a-synuclein deposition. [Extracted from the article]

A recent study conducted at the Indian Institute of Information Technology Allahabad focused on the interaction between Synphilin-1 and mutated alpha-synuclein in Parkinson's disease. The research highlighted the structural implications of these interactions and proposed a new method, AlphaLarge, to predict high-fidelity structures of large proteins like Synphilin-1. The study's findings could potentially lead to the development of targeted drugs for Parkinson's disease and other pathophysiologies involving large proteins with unknown structures. For more information, readers can refer to the article "A Structural Proteomics Exploration of Synphilin-1 and Alpha-Synuclein Interaction in Pathogenesis of Parkinson's Disease" published in Biomolecules. [Extracted from the article]